Avadel pharmaceuticals announces publication of real-world data highlighting the risk of accidental dosing errors with immediate-release twice-nightly oxybates

- adverse events were reported in patients who took the second, middle-of-the-night dose of immediate-release oxybate less than 2.5 hours after the first dose -

AVDL Ratings Summary

AVDL Quant Ranking